Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on November 22, 2021. The filing addresses corporate governance changes under Item 5.02, specifically the resignation of a director and the appointment of a new director to the Board.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Resignation: Mr. Kevan Clemens resigned from the Board of Directors effective immediately on November 22, 2021. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Mr. Sujay Kango was appointed to the Board on November 22, 2021, to fill the vacancy. He will serve the remainder of Mr. Clemens' term, expiring at the 2023 annual meeting of stockholders.
- Compensation: Mr. Kango received an initial stock option grant for 25,000 shares (vesting over three years) and a pro-rated grant for 33,334 shares (vesting over twelve months). The exercise price for these options is the closing price of MEI Pharma common stock on November 22, 2021.
Outlook, Risks, and Management Commentary
Management highlighted Mr. Kango's extensive background, including over 25 years of experience in pharmaceutical and biotechnology commercialization. His recent roles include Executive Vice President and Chief Commercial Officer at Acceleron Pharma and leadership positions at AbbVie, Infinity Pharmaceuticals, and Onyx Pharmaceuticals. The filing states there are no reportable related party transactions involving Mr. Kango and no family relationships with other directors or officers.
Key Facts for Investor Verification
- Verify the exact closing stock price of MEI Pharma on November 22, 2021, to determine the exercise price of the new director's options.
- Confirm the total number of shares authorized under the MEI Pharma, Inc. Amended and Restated 2008 Stock Omnibus Equity Compensation Plan to assess dilution impact.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the board change.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.